Frank N, Caesar R, Scherf H R, Wiessler M
J Cancer Res Clin Oncol. 1986;111(2):98-102. doi: 10.1007/BF00400744.
The effect of an in vivo treatment with the carboxylesterase inhibitor bis-p-nitrophenylphosphate (BNPP) on the hydrolysis of 1-(N-methyl-N-nitrosamino)-methylacetate (NNMA), 1-(N-methyl-N-nitrosamino)-methylbutyrate (NNMB), 1-(N-methyl-N-nitrosamino)-methylbenzoate (NNMBz) and 1-(N-methyl-N-nitrosamino)-methylpivaloate (NMMP) in rat tissue homogenates was studied. The rates of hydrolysis were specific for each compound and different in every organ tested; the extent of inhibition of the hydrolysis by BNPP was also substrate and organ specific. In some cases no inhibition at all was observed. The rate of elimination of NNMA, NNMB, and NNMP from blood was not influenced by BNPP pretreatment. The LD50 of NNMA after i.v. application showed a rise of 85% with a BNPP pretreatment. BNPP also influenced the carcinogenicity of NNMA, whereby the total carcinogenic potency was not altered, but the organotropism had changed slightly.
研究了用羧酸酯酶抑制剂双对硝基苯基磷酸酯(BNPP)进行体内处理对大鼠组织匀浆中1-(N-甲基-N-亚硝基氨基)-乙酸甲酯(NNMA)、1-(N-甲基-N-亚硝基氨基)-丁酸甲酯(NNMB)、1-(N-甲基-N-亚硝基氨基)-苯甲酸甲酯(NNMBz)和1-(N-甲基-N-亚硝基氨基)-新戊酸甲酯(NMMP)水解的影响。每种化合物的水解速率具有特异性,且在所测试的每个器官中都不同;BNPP对水解的抑制程度也具有底物和器官特异性。在某些情况下,根本未观察到抑制作用。血液中NNMA、NNMB和NMMP的消除速率不受BNPP预处理的影响。静脉注射后NNMA的半数致死剂量(LD50)在BNPP预处理后升高了85%。BNPP还影响了NNMA的致癌性,其中总致癌效力未改变,但器官嗜性略有变化。